Korean J Gastroenterol.  2023 Feb;81(2):72-85. 10.4166/kjg.2023.011.

Treatment of Autoimmune Hepatitis

• Kim JK

• KMID: 2539576
• DOI: http://doi.org/10.4166/kjg.2023.011

Abstract

Autoimmune hepatitis (AIH) is a chronic liver disease, characterized by elevated levels of transaminases, immunoglobulin G, and positive autoantibodies. The disease course is dynamic and presents heterogeneous disease manifestations at diagnosis. This review summarizes the issues regarding the treatment and monitoring of AIH in adult patients. Glucocorticoids and azathioprine are the first line of treatment. Alternative first-line treatments include budesonide or mycophenolate mofetil (MMF). Although no randomized controlled trials have been performed, MMF, cyclosporine, tacrolimus, 6-mercaptopurine, 6-thioguanine, allopurinol, sirolimus, everolimus, infliximab, or rituximab have been attempted in patients not responding to or intolerant to first-line treatments. Most patients require life-long special monitoring, with or without maintenance treatment.

Keyword

Adult; Autoimmune hepatitis; Treatment

Figure

• 

  Fig. 1 Induction strategy for autoimmune hepatitis as per the autoimmune hepatitis clinical practice guidelines of KASL (figure courtesy of the KASL). AIH, autoimmune hepatitis; AZA, azathioprine; DILI, drug-induced liver injury; HAI, hepatitis activity index; NUDT15, Nudix hydrolase 15; TPMT, thiopurine S-methyltransferase; KASL, Korean Association for the Study of the Liver. *Delayed institution of AZA by 2 weeks can be considered. †Emergent evaluation for liver transplantation should be considered for patients with acute liver failure.

• 

  Fig. 2 Maintenance strategy for patients with autoimmune hepatitis depicting the biochemical response to prednisolone and/or azathioprine induction therapy; extracted from the autoimmune hepatitis clinical practice guidelines of KASL (figure courtesy of the KASL). 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine; AZA, azathioprine; MMF, mycophenolate mofetil; KASL, Korean Association for the Study of the Liver.

Reference

1. Krawitt EL. 2006; Autoimmune hepatitis. N Engl J Med. 354:54–66. DOI: 10.1056/NEJMra050408. PMID: 16394302.

2. Cook GC, Mulligan R, Sherlock S. 1971; Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 40:159–185. DOI: 10.1093/oxfordjournals.qjmed.a067264. PMID: 4933363.

3. Soloway RD, Summerskill WH, Baggenstoss AH, et al. 1972; Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 63:820–833. DOI: 10.1016/S0016-5085(19)33223-8. PMID: 4538724.

4. Murray-Lyon IM, Stern RB, Williams R. 1973; Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1:735–737. DOI: 10.1016/S0140-6736(73)92125-9. PMID: 4121073.

5. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. 1975; Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 16:876–883. DOI: 10.1136/gut.16.11.876. PMID: 1104411. PMCID: PMC1413126.

6. Tage-Jensen U, Schlichting P, Aldershvile J, et al. 1982; Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification. Liver. 2:95–103. DOI: 10.1111/j.1600-0676.1982.tb00184.x. PMID: 7176845.

7. Muratori P, Lalanne C, Barbato E, et al. 2016; Features and progression of asymptomatic autoimmune hepatitis in Italy. Clin Gastroenterol Hepatol. 14:139–146. DOI: 10.1016/j.cgh.2015.07.017. PMID: 26192146.

8. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. 2005; Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 42:53–62. DOI: 10.1002/hep.20732. PMID: 15954109.

9. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. 2002; Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 35:75–81. DOI: 10.1097/00004836-200207000-00016. PMID: 12080231.

10. Czaja AJ. 2009; Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 29:816–823. DOI: 10.1111/j.1478-3231.2008.01904.x. PMID: 19018980.

11. Gordon V, Adhikary R, Appleby V, et al. UK Multi-Centre AIH Audit Group (see acknowledgements for other contributors). Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres. Liver Int. 2022; Mar. 14. doi: 10.1111/liv.15241. DOI: 10.1111/liv.15241. PMID: 35286013.

12. Montano Loza AJ, Czaja AJ. 2007; Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol. 4:202–214. DOI: 10.1038/ncpgasthep0768. PMID: 17404588.

13. Manns MP, Czaja AJ, Gorham JD, et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51:2193–2213. DOI: 10.1002/hep.23584. PMID: 20513004.

14. Montano-Loza AJ, Carpenter HA, Czaja AJ. 2007; Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 102:1005–1012. DOI: 10.1111/j.1572-0241.2007.01153.x. PMID: 17319926.

15. Mack CL, Adams D, Assis DN, et al. 2020; Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 72:671–722. DOI: 10.1002/hep.31065. PMID: 31863477.

16. Lohse AW, Sebode M, Bhathal PS, et al. 2022; Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int. 42:1058–1069. DOI: 10.1111/liv.15217. PMID: 35230735.

17. Miyake Y, Iwasaki Y, Terada R, et al. 2006; Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 24:1197–1205. DOI: 10.1111/j.1365-2036.2006.03113.x. PMID: 17014578.

18. Hoeroldt B, McFarlane E, Dube A, et al. 2011; Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 140:1980–1989. DOI: 10.1053/j.gastro.2011.02.065. PMID: 21396370.

19. Laschtowitz A, Zachou K, Lygoura V, et al. 2021; Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP Rep. 3:100321. DOI: 10.1016/j.jhepr.2021.100321. PMID: 34381983. PMCID: PMC8333110.

20. Dhaliwal HK, Hoeroldt BS, Dube AK, et al. 2015; Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol. 110:993–999. DOI: 10.1038/ajg.2015.139. PMID: 26010310.

21. Pape S, Snijders RJALM, Gevers TJG, et al. International Autoimmune Hepatitis Group (IAIHG) collaborators. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022; 76:841–849. DOI: 10.1016/j.jhep.2021.12.041. PMID: 35066089.

22. Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. 2010; Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology. 52:1857author reply 1857–1858. DOI: 10.1002/hep.23924. PMID: 20931560.

23. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. 2004; Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 99:1510–1516. DOI: 10.1111/j.1572-0241.2004.30457.x. PMID: 15307869.

24. Lüth S, Herkel J, Kanzler S, et al. 2008; Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 42:926–930. DOI: 10.1097/MCG.0b013e318154af74. PMID: 18645526.

25. Lamers MM, van Oijen MG, Pronk M, Drenth JP. 2010; Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 53:191–198. DOI: 10.1016/j.jhep.2010.01.037. PMID: 20400196.

26. European Association for the Study of the Liver. 2015; EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 63:971–1004. Erratum in: J Hepatol 2015;63:1543-1544. DOI: 10.1016/j.jhep.2015.09.016.

27. Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. 2017; Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis. Dig Dis Sci. 62:2900–2907. DOI: 10.1007/s10620-017-4728-2. PMID: 28871464.

28. Pape S, Gevers TJG, Belias M, et al. 2019; Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 17:2068–2075.e2. DOI: 10.1016/j.cgh.2018.12.035. PMID: 30625402.

29. Zhang C, Wu SS, Dong XQ, Wu Z, Zhao H, Wang GQ. 2019; The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis. Medicine (Baltimore). 98:e18313. DOI: 10.1097/MD.0000000000018313. PMID: 31876706. PMCID: PMC6946338.

30. Lohse AW, Mieli-Vergani G. 2011; Autoimmune hepatitis. J Hepatol. 55:171–182. DOI: 10.1016/j.jhep.2010.12.012. PMID: 21167232.

31. Relling MV, Schwab M, Whirl-Carrillo M, et al. 2019; Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 105:1095–1105. DOI: 10.1002/cpt.1304. PMID: 30447069. PMCID: PMC6576267.

32. Stellon AJ, Hegarty JE, Portmann B, Williams R. 1985; Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet. 1:668–670. DOI: 10.1016/S0140-6736(85)91329-7. PMID: 2858619.

33. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. 1988; Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 8:781–784. DOI: 10.1002/hep.1840080414. PMID: 3292363.

34. Stern RB, Wilkinson SP, Howorth PJ, Williams R. 1977; Controlled trial of synthetic D-penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut. 18:19–22. DOI: 10.1136/gut.18.1.19. PMID: 320109. PMCID: PMC1411250.

35. Johnson PJ, McFarlane IG, Williams R. 1995; Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 333:958–963. DOI: 10.1056/NEJM199510123331502. PMID: 7666914.

36. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. 2006; Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol. 45:584–591. DOI: 10.1016/j.jhep.2006.05.011. PMID: 16876902.

37. Czaja AJ, Carpenter HA. 2006; Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci. 51:968–975. DOI: 10.1007/s10620-006-9336-5. PMID: 16773433.

38. Czaja AJ. 2008; Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 7:319–333. DOI: 10.1517/14740338.7.3.319. PMID: 18462189.

39. Czaja AJ, Lindor KD. 2000; Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 119:1312–1316. DOI: 10.1053/gast.2000.0010000001. PMID: 11054389.

40. Manns MP, Jaeckel E, Taubert R. 2018; Budesonide in autoimmune hepatitis: the right drug at the right time for the right patient. Clin Gastroenterol Hepatol. 16:186–189. DOI: 10.1016/j.cgh.2017.11.003. PMID: 29128475.

41. Peiseler M, Liebscher T, Sebode M, et al. 2018; Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 16:260–267.e1. DOI: 10.1016/j.cgh.2016.12.040. PMID: 28126427.

42. Manns MP, Woynarowski M, Kreisel W, et al. European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010; 139:1198–1206. DOI: 10.1053/j.gastro.2010.06.046. PMID: 20600032.

43. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. 2003; Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 9:2681–2685. DOI: 10.3748/wjg.v9.i12.2681. PMID: 14669312. PMCID: PMC4612031.

44. Efe C, Ozaslan E, Kav T, et al. 2012; Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. 11:330–334. DOI: 10.1016/j.autrev.2011.09.006. PMID: 22001521.

45. Zachou K, Gatselis NK, Arvaniti P, et al. 2016; A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther. 43:1035–1047. DOI: 10.1111/apt.13584. PMID: 26991238.

46. Yu ZJ, Zhang LL, Huang TT, Zhu JS, He ZB. 2019; Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 31:873–877. DOI: 10.1097/MEG.0000000000001367. PMID: 31150366.

47. Yeoman AD, Westbrook RH, Zen Y, et al. 2011; Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 53:926–934. DOI: 10.1002/hep.24141. PMID: 21374663.

48. Czaja AJ. 2007; Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 13:953–955. DOI: 10.1002/lt.21088. PMID: 17600348.

49. Rahim MN, Liberal R, Miquel R, Heaton ND, Heneghan MA. 2019; Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? Liver Transpl. 25:946–959. DOI: 10.1002/lt.25451. PMID: 30900368.

50. Ichai P, Duclos-Vallée JC, Guettier C, et al. 2007; Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 13:996–1003. DOI: 10.1002/lt.21036. PMID: 17370335.

51. Yeoman AD, Westbrook RH, Zen Y, et al. 2014; Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol. 61:876–882. DOI: 10.1016/j.jhep.2014.05.021. PMID: 24842305.

52. Zachou K, Arvaniti P, Azariadis K, et al. 2019; Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Hepatol Res. 49:96–104. DOI: 10.1111/hepr.13252. PMID: 30248210.

53. Czaja AJ. 2013; Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci. 58:897–914. DOI: 10.1007/s10620-012-2445-4. PMID: 23090425.

54. Karkhanis J, Verna EC, Chang MS, et al. Acute Liver Failure Study Group. Steroid use in acute liver failure. Hepatology. 2014; 59:612–621. DOI: 10.1002/hep.26678. PMID: 23929808. PMCID: PMC4881740.

55. Hartl J, Ehlken H, Weiler-Normann C, et al. 2015; Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol. 62:642–646. DOI: 10.1016/j.jhep.2014.10.018. PMID: 25457202.

56. Wang G, Tanaka A, Zhao H, et al. 2021; The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 15:223–257. DOI: 10.1007/s12072-021-10170-1. PMID: 33942203. PMCID: PMC8144150.

57. Guirguis J, Alonso Y, Lopez R, Carey W. 2018; Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance. Gastroenterol Rep (Oxf). 6:284–290. DOI: 10.1093/gastro/goy020. PMID: 30430017. PMCID: PMC6225821.

58. Choi J, Choi GH, Lee D, et al. 2019; Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country. Liver Int. 39:985–994. DOI: 10.1111/liv.14082. PMID: 30821090.

59. Czaja AJ. 2010; Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci. 55:1761–1769. DOI: 10.1007/s10620-010-1243-0. PMID: 20428945.

60. Czaja AJ, Ammon HV, Summerskill WH. 1980; Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology. 78:518–523. DOI: 10.1016/0016-5085(80)90866-5. PMID: 7351290.

61. Montano-Loza AJ, Carpenter HA, Czaja AJ. 2007; Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 27:507–515. DOI: 10.1111/j.1478-3231.2007.01444.x. PMID: 17403191.

62. Srivastava S, Boyer JL. 2010; Psychological stress is associated with relapse in type 1 autoimmune hepatitis. Liver Int. 30:1439–1447. DOI: 10.1111/j.1478-3231.2010.02333.x. PMID: 20849437. PMCID: PMC3735904.

63. van Gerven NM, Verwer BJ, Witte BI, et al. Dutch Autoimmune Hepatitis Working Group. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013; 58:141–147. DOI: 10.1016/j.jhep.2012.09.009. PMID: 22989569.

64. Kil JS, Lee JH, Han AR, et al. 2010; Long-term treatment outcomes for autoimmune hepatitis in Korea. J Korean Med Sci. 25:54–60. DOI: 10.3346/jkms.2010.25.1.54. PMID: 20052348. PMCID: PMC2800017.

65. Czaja AJ, Carpenter HA. 2003; Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 23:116–123. DOI: 10.1034/j.1600-0676.2003.00810.x. PMID: 12654134.

66. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. 1983; Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 3:685–689. DOI: 10.1002/hep.1840030510. PMID: 6618435.

67. Czaja AJ, Menon KV, Carpenter HA. 2002; Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 35:890–897. DOI: 10.1053/jhep.2002.32485. PMID: 11915036.

68. Czaja AJ. 1990; Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology. 11:1044–1049. DOI: 10.1002/hep.1840110621. PMID: 2365282.

69. Harrison L, Gleeson D. 2019; Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)? Liver Int. 39:610–620. DOI: 10.1111/liv.14051. PMID: 30667576.

70. Seela S, Sheela H, Boyer JL. 2005; Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 25:734–739. DOI: 10.1111/j.1478-3231.2005.01141.x. PMID: 15998423.

71. Korean Association for the Study of the Liver (KASL). 2022; KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 28:276–331. Erratum in: Clin Mol Hepatol 2022;28:940. DOI: 10.3350/cmh.2022.0084.e1. PMID: 36068669. PMCID: PMC9597234.

72. Park SY, Gong HS, Kim KM, et al. 2018; Korean guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Metab. 25:195–211. DOI: 10.11005/jbm.2018.25.4.195. PMID: 30574464. PMCID: PMC6288607.

73. Buckley L, Humphrey MB. 2018; Glucocorticoid-Induced Osteoporosis. N Engl J Med. 379:2547–2556. DOI: 10.1056/NEJMcp1800214. PMID: 30586507.

74. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. 1980; Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 21:78–83. DOI: 10.1136/gut.21.1.78. PMID: 6988304. PMCID: PMC1419564.

75. Chang JY, Cheon JH. 2019; Thiopurine therapy in patients with inflammatory bowel disease: a focus on metabolism and pharmacogenetics. Dig Dis Sci. 64:2395–2403. DOI: 10.1007/s10620-019-05720-5. PMID: 31290039.

76. Yang SK, Hong M, Baek J, et al. 2014; A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 46:1017–1020. DOI: 10.1038/ng.3060. PMID: 25108385. PMCID: PMC4999337.

77. Matsuoka K. 2020; NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease. Intest Res. 18:275–281. DOI: 10.5217/ir.2020.00002. PMID: 32482022. PMCID: PMC7385579.

78. Kim HT, Choi R, Won HH, et al. 2017; NUDT15 genotype distributions in the Korean population. Pharmacogenet Genomics. 27:197–200. DOI: 10.1097/FPC.0000000000000274. PMID: 28277331.

79. Miao Q, Yan L, Zhou Y, et al. 2021; Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis. Sci Rep. 11:7984. DOI: 10.1038/s41598-021-87095-0. PMID: 33846471. PMCID: PMC8042108.

80. Sutiman N, Chen S, Ling KL, et al. 2018; Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. Pharmacogenomics. 19:31–43. DOI: 10.2217/pgs-2017-0147. PMID: 29210335. PMCID: PMC5753614.

81. Chang JY, Park SJ, Jung ES, et al. 2020; Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 18:2010–2018.e2. DOI: 10.1016/j.cgh.2019.08.034. PMID: 31446180.

82. Chao K, Huang Y, Zhu X, et al. 2021; Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. Aliment Pharmacol Ther. 54:1124–1133. DOI: 10.1111/apt.16600. PMID: 34563096.

83. Selvarajah V, Montano-Loza AJ, Czaja AJ. 2012; Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 36:691–707. DOI: 10.1111/apt.12042. PMID: 22973822.

84. Allison AC. 2005; Mechanisms of action of mycophenolate mofetil. Lupus. 14 Suppl 1:s2–8. DOI: 10.1177/096120330501400102.

85. Santiago P, Schwartz I, Tamariz L, Levy C. 2019; Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 49:830–839. DOI: 10.1111/apt.15157. PMID: 30761563.

86. Abdollahi M, Ekrami NK, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. 2020; Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol. 26:5896–5910. DOI: 10.3748/wjg.v26.i38.5896. PMID: 33132643. PMCID: PMC7579758.

87. Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G. 2021; A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis. 53:1381–1393. DOI: 10.1016/j.dld.2021.05.033. PMID: 34162505.

88. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. 1999; Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 94:241–248. DOI: 10.1111/j.1572-0241.1999.00807.x. PMID: 9934764.

89. Than NN, Wiegard C, Weiler-Normann C, et al. 2016; Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scand J Gastroenterol. 51:329–336. DOI: 10.3109/00365521.2015.1095351. PMID: 26458216.

90. Scott LJ, McKeage K, Keam SJ, Plosker GL. 2003; Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 63:1247–1297. DOI: 10.2165/00003495-200363120-00006. PMID: 12790696.

91. Brunet M, van Gelder T, Åsberg A, et al. 2019; Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 41:261–307. DOI: 10.1097/FTD.0000000000000640. PMID: 31045868.

92. Lohse AW, Sebode M, Jørgensen MH, et al. European Reference Network on Hepatological Diseases (ERN RARE-LIVER). International Autoimmune Hepatitis Group (IAIHG). Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J Hepatol. 2020; 73:1496–1506. DOI: 10.1016/j.jhep.2020.07.023. PMID: 32707224.

93. Hübener S, Oo YH, Than NN, et al. 2016; Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 14:445–453. DOI: 10.1016/j.cgh.2015.09.037. PMID: 26492846.

94. van den Brand FF, van Nieuwkerk CMJ, Verwer BJ, et al. 2018; Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. Aliment Pharmacol Ther. 48:761–767. DOI: 10.1111/apt.14939. PMID: 30109891. PMCID: PMC6175236.

95. Toksvang LN, Schmidt MS, Arup S, et al. 2019; Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. PLoS One. 14:e0212157. DOI: 10.1371/journal.pone.0212157. PMID: 31125338. PMCID: PMC6534292.

96. de Boer YS, van Gerven NM, de Boer NK, Mulder CJ, Bouma G, van Nieuwkerk CM. 2013; Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther. 37:640–646. DOI: 10.1111/apt.12223. PMID: 23347359.

97. Neuhaus P, Klupp J, Langrehr JM. 2001; mTOR inhibitors: an overview. Liver Transpl. 7:473–484. DOI: 10.1053/jlts.2001.24645. PMID: 11443573.

98. Chatrath H, Allen L, Boyer TD. 2014; Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 127:1128–1131. DOI: 10.1016/j.amjmed.2014.06.016. PMID: 24979741.

99. Ytting H, Larsen FS. 2015; Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol. 50:1025–1031. DOI: 10.3109/00365521.2014.998271. PMID: 25862144.

100. Weiler-Normann C, Schramm C, Quaas A, et al. 2013; Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 58:529–534. DOI: 10.1016/j.jhep.2012.11.010. PMID: 23178709.

101. Ghabril M, Bonkovsky HL, Kum C, et al. US Drug-Induced Liver Injury Network. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013; 11:558–564.e3. DOI: 10.1016/j.cgh.2012.12.025. PMID: 23333219. PMCID: PMC3865702.

102. Björnsson ES, Gunnarsson BI, Gröndal G, et al. 2015; Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 13:602–608. DOI: 10.1016/j.cgh.2014.07.062. PMID: 25131534.

103. Burak KW, Swain MG, Santodomingo-Garzon T, et al. 2013; Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 27:273–280. DOI: 10.1155/2013/512624. PMID: 23712302. PMCID: PMC3735730.

104. Chung YY, Heneghan MA. 2022; Autoimmune hepatitis in pregnancy: Pearls and pitfalls. Hepatology. 76:502–517. DOI: 10.1002/hep.32410. PMID: 35182079.

105. Braga A, Vasconcelos C, Braga J. 2020; Autoimmune hepatitis and pregnancy. Best Pract Res Clin Obstet Gynaecol. 68:23–31. DOI: 10.1016/j.bpobgyn.2020.03.007. PMID: 32376296.

106. Bozward AG, Wootton GE, Podstawka O, Oo YH. 2020; Autoimmune hepatitis: tolerogenic immunological state during pregnancy and immune escape in post-partum. Front Immunol. 11:591380. DOI: 10.3389/fimmu.2020.591380. PMID: 33072138. PMCID: PMC7541906.

107. Si T, Huang Z, Hegarty R, Ma Y, Heneghan MA. 2022; Systematic review with meta-analysis: outcomes of pregnancy in patients with autoimmune hepatitis. Aliment Pharmacol Ther. 55:1368–1378. DOI: 10.1111/apt.16924. PMID: 35393675. PMCID: PMC9324120.

108. Westbrook RH, Yeoman AD, Kriese S, Heneghan MA. 2012; Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun. 38:J239–244. DOI: 10.1016/j.jaut.2011.12.002. PMID: 22261501.

109. Sarkar M, Brady CW, Fleckenstein J, et al. 2021; Reproductive health and liver disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 73:318–365. DOI: 10.1002/hep.31559. PMID: 32946672.

110. Paizis K. 2019; Immunomodulatory drugs in pregnancy and lactation. Aust Prescr. 42:97–101. DOI: 10.18773/austprescr.2019.026. PMID: 31363308. PMCID: PMC6594853.

111. Park Y, Cho Y, Cho EJ, Kim YJ. 2015; Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes. Clin Mol Hepatol. 21:150–157. DOI: 10.3350/cmh.2015.21.2.150. PMID: 26157752. PMCID: PMC4493358.

112. Jiang Y, Xu BH, Rodgers B, Pyrsopoulos N. 2021; Characteristics and inpatient outcomes of primary biliary cholangitis and autoimmune hepatitis overlap syndrome. J Clin Transl Hepatol. 9:392–398. DOI: 10.14218/JCTH.2021.00008. PMID: 34221925. PMCID: PMC8237146.

113. To U, Silveira M. 2018; Overlap Syndrome of autoimmune hepatitis and primary biliary cholangitis. Clin Liver Dis. 22:603–611. DOI: 10.1016/j.cld.2018.03.010. PMID: 30259856.

114. Martínez Casas OY, Díaz Ramírez GS, Marín Zuluaga JI, et al. 2018; Autoimmune hepatitis - primary biliary cholangitis overlap syndrome. Long-term outcomes of a retrospective cohort in a university hospital. Gastroenterol Hepatol. 41:544–552. English, Spanish. DOI: 10.1016/j.gastre.2018.11.006.

115. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. 2008; Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 28:209–220. DOI: 10.1111/j.1365-2036.2008.03722.x. PMID: 18433467.

116. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. International Autoimmune Hepatitis Group. 2011; Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 54:374–385. DOI: 10.1016/j.jhep.2010.09.002. PMID: 21067838.

117. Jeong EH, Jun DW, Cho YK, et al. 2013; Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol. 19:266–272. DOI: 10.3350/cmh.2013.19.3.266. PMID: 24133664. PMCID: PMC3796676.

118. Zachou K, Azariadi K, Lytvyak E, et al. 2019; Nonalcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: Important player or innocent bystander? J Hepatol. 70:e396–397. DOI: 10.1016/S0618-8278(19)30779-0.

119. De Luca-Johnson J, Wangensteen KJ, Hanson J, Krawitt E, Wilcox R. 2016; Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease. Dig Dis Sci. 61:2710–2720. DOI: 10.1007/s10620-016-4213-3. PMID: 27262844. PMCID: PMC6357773.

120. Adams LA, Lindor KD, Angulo P. 2004; The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 99:1316–1320. DOI: 10.1111/j.1572-0241.2004.30444.x. PMID: 15233671.

121. Yatsuji S, Hashimoto E, Kaneda H, Taniai M, Tokushige K, Shiratori K. 2005; Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol. 40:1130–1138. DOI: 10.1007/s00535-005-1711-z. PMID: 16378177.

122. Jeong SH. 2018; Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. Clin Mol Hepatol. 24:10–19. DOI: 10.3350/cmh.2017.0066. PMID: 29307132. PMCID: PMC5875193.

123. Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. 2017; Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS One. 12:e0182391. DOI: 10.1371/journal.pone.0182391. PMID: 28771543. PMCID: PMC5542613.

124. Mendes F, Couto CA, Levy C. 2011; Recurrent and de novo autoimmune liver diseases. Clin Liver Dis. 15:859–878. DOI: 10.1016/j.cld.2011.08.008. PMID: 22032533.

125. Cho CW, Kwon CHD, Kim JM, Choi GS, Joh JW, Lee SK. 2017; Comparative analysis of the clinical outcomes of liver transplantation for probable and definite auto-immune hepatitis by international diagnostic scoring criteria. Transplant Proc. 49:1126–1128. DOI: 10.1016/j.transproceed.2017.03.014. PMID: 28583541.

126. Kwon JH, Hanouneh IA, Allende D, et al. 2018; De novo autoimmune hepatitis following liver transplantation. Transplant Proc. 50:1451–1456. DOI: 10.1016/j.transproceed.2018.02.066. PMID: 29880369.

127. Hayashi M, Keeffe EB, Krams SM, et al. 1998; Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg. 4:208–214. DOI: 10.1002/lt.500040313. PMID: 9563959.

128. Vogel A, Heinrich E, Bahr MJ, et al. 2004; Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 18:62–69. DOI: 10.1111/j.1399-0012.2004.00117.x. PMID: 15108772.

129. Demetris AJ, Sebagh M. 2008; Plasma cell hepatitis in liver allografts: Variant of rejection or autoimmune hepatitis? Liver Transpl. 14:750–755. DOI: 10.1002/lt.21518. PMID: 18508366.

130. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. 2014; Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 27:1039–1049. DOI: 10.1111/tri.12372. PMID: 24943720.

131. Chen K, Sheng J, Ma B, et al. 2019; Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients. Transplantation. 103:929–937. DOI: 10.1097/TP.0000000000002647. PMID: 30747839.

132. Rigopoulou EI, Dalekos GN. 2021; Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases. Cancers (Basel). 13:1023. DOI: 10.3390/cancers13051023. PMID: 33804480. PMCID: PMC7957658.

133. Reig M, Forner A, Rimola J, et al. 2022; BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 76:681–693. DOI: 10.1016/j.jhep.2021.11.018. PMID: 34801630.

134. Haanen JBAG, Carbonnel F, Robert C, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv119–iv142. Erratum in: Ann Oncol 2018;29(Suppl 4):iv264-iv266. DOI: 10.1093/annonc/mdx225. PMID: 28881921.

135. Pinter M, Scheiner B, Peck-Radosavljevic M. 2021; Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 70:204–214. DOI: 10.1136/gutjnl-2020-321702. PMID: 32747413. PMCID: PMC7788203.